Shionogi

4507.TApproved

Shionogi Inc. is a global pharmaceutical company with over 140 years of experience in drug discovery and development, headquartered in Japan with significant US operations. The company specializes in addressing unmet medical needs through innovative treatments for infectious diseases, antivirals, and complex therapeutic areas. Shionogi has built strategic partnerships with industry, government agencies, and biotech companies to advance science with urgency, particularly in response to global health challenges like antimicrobial resistance and COVID-19. The company operates as a publicly traded entity with a strong commitment to ethical business practices and transparent operations.

Market Cap

$18.0B

Founded

1878

Focus

Small Molecules

4507.T · Stock Price

USD 3367.00+818.67 (+32.13%)

Historical price data

AI Company Overview

Technology Platform

Discovery-based pharmaceutical platform specializing in small molecule drug development with particular expertise in infectious diseases, antivirals, and novel antibiotic discovery since the 1950s.

Pipeline Snapshot

143

143 drugs in pipeline, 38 in Phase 3

Drug	Indication	Stage
Naldemedine + Placebo	Opioid-Induced Constipation (OIC)	Approved
Cefiderocol	Cystic Fibrosis	Approved
Statin	Ischemic Stroke	Approved
Rosuvastatin + HMG CoA inhibitor	Hypercholesteremia	Approved
Cefiderocol	Drug Clearance After Severe Burn Injury	Approved

FDA Approved Drugs

FETROJANDANov 14, 2019

MULPLETANDAJul 31, 2018

METHYLINNDADec 19, 2002

Opportunities

Significant growth opportunities exist through their investigational COVID-19 oral antiviral, expansion into neurological conditions like Fragile X syndrome, and development programs in high-value markets including oncology and metabolic disorders.

Strategic partnerships with government agencies and biotechnology companies provide additional avenues for portfolio expansion and risk mitigation.

Risk Factors

Key risks include regulatory challenges in novel antibiotic approval processes, competitive pressure in established HIV and influenza markets from patent expirations and biosimilars, and clinical development risks as the company expands into new therapeutic areas with less historical experience.

Global supply chain complexities and manufacturing challenges for innovative drug formulations present additional operational risks.

Competitive Landscape

Shionogi competes with major pharmaceutical companies including Pfizer, Merck, and Johnson & Johnson in infectious diseases, while facing specific competition from Gilead Sciences and ViiV Healthcare in HIV therapeutics. The company differentiates through its specialized focus on novel antibiotics, strong Asian market presence, and 140+ year heritage in drug discovery, particularly its proven track record in antibiotic development since the 1950s.

Publications

Patents

Pipeline

143

FDA Approvals